First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina
Arch Bronconeumol. 2015 Oct;51(10):e49-52.
doi: 10.1016/j.arbres.2015.03.012.
Epub 2015 May 27.
[Article in
English,
Spanish]
Affiliations
- 1 Instituto Prof. Dr. Raúl Vaccarezza, Hospital de Infecciosas Dr. F.J. Muñiz, Buenos Aires, Argentina. Electronic address: [email protected].
- 2 Instituto Prof. Dr. Raúl Vaccarezza, Hospital de Infecciosas Dr. F.J. Muñiz, Buenos Aires, Argentina.
Abstract
XDR (extensively drug-resistant) and pre-XDR tuberculosis (TB) seriously compromise prognosis and treatment possibilities, and inevitably require the use of group V drugs (World Health Organization). The progress of all patients with XDR and pre-XDR TB seen in a specialized unit during 2012 and 2013 and treated with regimens that included at least 6 months of meropenem-clavulanate (MPC), capreomycin, moxifloxacin, linezolid, clofazimine, high-dose isoniazid, PAS, and bedaquiline in 1 case, were retrospectively analysed. Ten patients were treated, 9 with an extensive pattern of resistance to at least 6 drugs, and 1 because of adverse reactions and drug interactions leading to a similar situation. Eight of the 10 patients treated achieved bacteriological sputum conversion (2 consecutive negative monthly cultures) over a period of 2-7 months, while 2 died. No adverse reactions attributable to prolonged administration of MPC were observed.
Keywords:
Carbapenems; Clavulanate; Clavulanato; Meropenem; TB-XDR; Tuberculosis; XDR-TB.
Copyright © 2014 SEPAR. Published by Elsevier Espana. All rights reserved.
MeSH terms
-
Adult
-
Antitubercular Agents / classification
-
Antitubercular Agents / pharmacology
-
Antitubercular Agents / therapeutic use*
-
Argentina / epidemiology
-
Clavulanic Acid / pharmacology
-
Clavulanic Acid / therapeutic use*
-
Drug Therapy, Combination
-
Extensively Drug-Resistant Tuberculosis / drug therapy*
-
Extensively Drug-Resistant Tuberculosis / epidemiology
-
Female
-
Humans
-
Male
-
Meropenem
-
Middle Aged
-
Mycobacterium tuberculosis / drug effects
-
Mycobacterium tuberculosis / isolation & purification
-
Peru / ethnology
-
Retrospective Studies
-
Sputum / microbiology
-
Thienamycins / pharmacology
-
Thienamycins / therapeutic use*
-
Treatment Outcome
-
Tuberculosis, Multidrug-Resistant / drug therapy
-
Tuberculosis, Multidrug-Resistant / epidemiology
-
Uruguay / ethnology
-
Young Adult
Substances
-
Antitubercular Agents
-
Thienamycins
-
Clavulanic Acid
-
Meropenem